EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD

Slideshow

A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?

   

Recent Videos
Deepak Bhatt, MD, MPH, MBA | Credit: Mount Sinai Heart
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Siddharth Patel, MD, MPH | Credit: TIMI Study Group
Kausik Ray, MD, MPhil | Credit: BAIM Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Kenneth Mahaffey, MD | Credit: Stanford University
Sara Diaz Saravia, MD | Credit: X.com
Deepak Bhatt, MD, MPH, MBA | Credit: Mount Sinai Heart
Related Content
FDA Grants Breakthrough Therapy Designation to Plozasiran for FCS | Image Credit: FDA

FDA Grants Breakthrough Therapy Designation to Plozasiran for FCS

Connor Iapoce
September 12th 2024
Article
default thumbnail for Don't Miss a Beat podcast.

Don't Miss a Beat: Finerenone's Role in Heart Failure from ESC Congress Data

Muthiah Vaduganathan, MD, MPH;Stephen Greene, MD
September 2nd 2024
Podcast
Stock image of a woman experiencing chest pain. | Credit: Fotolia

Study Finds Traditional Risk Scores Miss Most Patients at Risk of First Heart Attack

Patrick Campbell
September 9th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: First 10 Prices Announced from CMS Price Negotiations

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
August 19th 2024
Podcast
Deepak Bhatt, MD, MPH, MBA | Credit: Mount Sinai Heart

ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA

September 5th 2024
Article
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University

Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS

Patrick Campbell
September 4th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.